Non-coding RNA Regulators Modulating FOXO1 and ETV6

The patent uses intermediate non-coding RNA regulators (miRNAs, siRNAs, antisense oligonucleotides) as mediators to modulate the expression of FOXO1 and ETV6 transcription factors. These intermediaries specifically bind to target mRNA sequences to suppress translation or promote degradation, thereby restoring splicing factor expression without directly manipulating the complex signaling pathways. This intermediary approach simplifies the therapeutic strategy while achieving reliable splicing factor restoration.

The patent employs RNA regulators with highly specific sequence complementarity to FOXO1 and ETV6 mRNA targets. This local specificity ensures that only the intended transcription factors are modulated, minimizing off-target effects on other components of the ERK and AKT pathways. The localized action at the mRNA level allows precise control of FOXO1 and ETV6 expression without broadly affecting the entire signaling network, thereby reducing harmful off-target effects while maintaining an appropriate therapeutic window.

The patent applies partial modulation of FOXO1 and ETV6 expression through RNA regulators, achieving sufficient suppression to restore splicing factor expression and promote cell cycle re-entry, but avoiding complete elimination of these transcription factors. This partial action maintains enough FOXO1 and ETV6 activity to prevent uncontrolled proliferation while providing enough suppression to reverse cellular senescence. The dose-dependent nature of RNA regulator action allows fine-tuning to achieve the optimal balance between promoting cell cycle re-entry and preventing malignant transformation.